Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder

Last updated: August 15, 2024
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting

Phase

N/A

Condition

Spinal Cord Injuries

Treatment

Fixed-dose TTNS Protocol

Variable-dose TTNS Protocol 2 x week

Variable-dose TTNS Protocol 5 x week

Clinical Study ID

NCT04350359
HSC-MS-19-0756
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to determine if electric stimulation to the leg, called transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute spinal cord injury.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-75 years old

  • Traumatic or non-traumatic SCI

  • Admitted to inpatient rehabilitation within 6 weeks

  • T9 level of injury and above who are at greatest risk of morbid NGB

  • Regionally located to allow follow-up

  • English or Spanish speaking

Exclusion

Exclusion Criteria:

  • History of genitourinary diagnoses (i.e. prostate hypertrophy, overactive bladder,cancer, etc.)

  • History of central nervous system disorder (i.e. prior SCI, stroke, brain injury,Parkinson's disease, MS, etc.)

  • History of peripheral neuropathy

  • pre-SCI symptoms of peripheral neuropathy (numbness and/or tingling in feet,sharp/jabbing/burning pain in feet, sensitivity to touch, lack of coordination,muscle weakness, etc.)

  • Pregnancy

  • Known injury to the lumbosacral spinal cord or plexus, or pelvis with associatedneuropathy

  • concern for tibial nerve pathway injury

  • absence of toe flexion or autonomic dysreflexia during electric stimulation test

  • Potential for progressive SCI including neurodegenerative SCI, ALS, cancermyelopathy, Multiple sclerosis, transverse myelitis

Study Design

Total Participants: 120
Treatment Group(s): 3
Primary Treatment: Fixed-dose TTNS Protocol
Phase:
Study Start date:
June 08, 2020
Estimated Completion Date:
December 01, 2025

Study Description

The purpose of this study is to see how well TTNS works at preventing incontinence in people with paraplegia from SCI that perform intermittent catheterization to empty their bladder. This study will compare the effectiveness of TTNS at 2 doses, fixed-dose and variable-dose. It will also evaluate the frequency of use, 2 days weekly compared to 5 days weekly.

Based on our pilot trials, tibial nerve stimulation protocols use submotor current intensity with a duration of 200 µs and a frequency of 20Hz. The experimental group will use a submotor "variable dose." The fixed-dose group will use submotor at current intensity at 1mA and designated as "fixed-dose."

TTNS will be used 5 days weekly, per our pilot trial. At 4-months post-SCI, the subject will be instructed to switch to 2x daily if he or she was randomized into the variable dose group of 2 days weekly and thus continue to doing so for the remainder of study participation. Because there is support in the literature for reduced doses of tibial nerve stimulation required for maintenance (1-3x weekly), the RCT includes this frequency comparison arm. All subjects will continue for 1-year post-SCI.

Additionally, we are collecting surveys to help identify characteristics of people (resilience and confidence) and adherence to medication and TTNS use throughout the study.

Connect with a study center

  • MedStar National Rehabilitation Hospital

    Washington, District of Columbia 20010
    United States

    Active - Recruiting

  • TIRR Memorial Hermann Research Center

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.